- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02885857
Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Research purpose: Safety and efficacy of long-term application of Shenyankangfu Tablets in Large sample of patients with chronic kidney disease.
The crowd: patients with primary glomerular nephritis, diabetic nephropathy patients.
Study design: a multicenter clinical study design, openness. The study drug: Shenyan Kangfu Tablets. Statistical analysis: Research plan is determined, by statistical professionals responsible for negotiation with the principal investigator for statistical analysis plan.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
Beijing
-
Beijing, Beijing, China
- Recrutamento
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences
-
Beijing, Beijing, China, 100853
- Recrutamento
- National Clinical Research Center for Kidney Disease, State Key Laboratory of Kidney Disease, Department of Nephrology, Chinese PLA General Hospital
-
Contato:
- jie wu, doctor
- E-mail: wujie301@163.com
-
Investigador principal:
- xiangmei chen, doctor
-
-
Chongqing
-
Chongqing, Chongqing, China
- Recrutamento
- Daping Hospital,Research Institute of Surgery Third Military Medical University
-
-
Fujian
-
Fuzhou, Fujian, China
- Recrutamento
- Fuzhou General Hospital Nanjing Military Command
-
Xiamen, Fujian, China
- Recrutamento
- 174th hospital of the People's Liberation Army
-
-
Hebei
-
Qinhuangdao, Hebei, China
- Recrutamento
- Beidaihe Sanatorium of Beijing Military Mrca
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Recrutamento
- Heilongjiang University of Chinese Medicine
-
-
Henan
-
Zhengzhou, Henan, China
- Recrutamento
- Henan Provincial People's Hospital
-
-
Shandong
-
Jinan, Shandong, China
- Recrutamento
- Shandong Province Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recrutamento
- Changhai Hospital of Shanghai
-
Shanghai, Shanghai, China
- Recrutamento
- LONGHUA Hospital Shanghai University of TCM
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Recrutamento
- First Hospital Of ShanXi Medical University
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recrutamento
- First Teaching Hospital of Tianjin University of TCM
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosed with primary glomerulonephritis or diabetic nephropathy;
- Aged from 18 to 70 years,male or female
- GFR≥45ml/min/1.73㎡
- 0.5g≤24 hours proteinuria≤3.0g
- glycated hemoglobin (HbAlc) ≤8% (This has been limited to patients with diabetic nephropathy)
- Traditional Chinese medicine syndrome conform Qi-Yin Deficiency
- Obtain the agreement of patients or their guardians, and signed informed consent file
Exclusion Criteria:
- Secondary nephropathy
- People allergic to Shenyankangfu tables
- Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life
- Pregnant or lactating women
- Be participating in another clinical study at the same period
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Shenyan kangfu Tablets
Shenyan Kangfu Tablets;Each weighing 0.48g;Oral;Once five, three times a day
|
Observation period: 24 weeks.
The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
24-hour urinary protein excretion
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Serum creatinine
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Glomerular filtration rate
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Albumin
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Glycated hemoglobin
Prazo: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Observations of the project value and the percentage change in value before and after the treatment.
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Symptom scores
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Routine blood test
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Routine urine test
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Liver function
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Renal function tests
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Potassium detection
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
blood glucose testing
Prazo: Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times
|
|
Electrocardiograph
Prazo: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
|
chest radiography
Prazo: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
|
Adverse events / adverse reactions
Prazo: Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Follow-up 3 times.Subject at any time to contact your doctor.
|
Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: YongLi Zhan, investigator, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Investigador principal: HongTao Yang, investigator, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Investigador principal: Meng Liang, investigator, 174th hospital of the People's Liberation Army
- Investigador principal: Lu Ma, investigator, Beidaihe Sanatorium of Beijing Military Mrca
- Investigador principal: LiQun Song, investigator, Heilongjiang University of Chinese Medicine
- Investigador principal: QiaoLing Zhou, investigator, Xiangya Hospital of Central South University
- Investigador principal: Ping Luo, investigator, Second Hospital of Jilin University
- Investigador principal: RongShan Li, investigator, Shanxi provincial peple's hospital
- Investigador principal: XiaoHong Cheng, investigator, Shaanxi Traditional Chinese Medicine Hospital
- Investigador principal: Jie Wu, investigator, Chinese PLA General Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- S2015-023-02
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Shenyan Kangfu Tablet
-
Shanghai University of Traditional Chinese MedicineRecrutamentoDoença Pulmonar Intersticial | Síndrome de Sjögren primáriaChina
-
Jiangsu HengRui Medicine Co., Ltd.Ativo, não recrutando
-
Columbia UniversityNational Library of Medicine (NLM); Agency for Healthcare Research and Quality...ConcluídoPaciente internadoEstados Unidos
-
AlexionRecrutamento
-
PMG Pharm Co., LtdConcluídoOsteoartrite do JoelhoRepublica da Coréia
-
China Academy of Chinese Medical SciencesPeking University First Hospital; Peking Union Medical College Hospital; Chengdu... e outros colaboradoresDesconhecido
-
Federal University of the Valleys of Jequitinhonha...Fundação de Amparo à Pesquisa do estado de Minas GeraisAinda não está recrutandoDesenvolvimento infantil
-
Xuanzhu Biopharmaceutical Co., Ltd.RecrutamentoEsteato-hepatite não alcoólica (NASH)China
-
Beijing Tide Pharmaceutical Co., LtdRecrutamentoPacientes com Tumores Sólidos AvançadosChina
-
Shenzhen Yangli Pharmaceutical Technology Co., LtdRecrutamentoCâncer de Mama Metastático | ER+, HER2- Câncer de Mama AvançadoChina